0001636282-26-000102.txt : 20260810 0001636282-26-000102.hdr.sgml : 20260810 20260810213151 ACCESSION NUMBER: 0001636282-26-000102 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260807 FILED AS OF DATE: 20260810 DATE AS OF CHANGE: 20260810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Albers Jeffrey W. CENTRAL INDEX KEY: 0001638474 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 261260399 MAIL ADDRESS: STREET 1: C/O ATLAS VENTURE STREET 2: 300 TECHNOLOGY SQ, 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 4 1 wk-form4_1786411908.xml FORM 4 X0609 4 2026-08-07 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001638474 Albers Jeffrey W. false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 1 0 0 0 1 Common Stock 2026-08-07 4 M 0 5000 10.39 A 5000 D Common Stock 2026-08-07 4 S 0 5000 104.47 D 0 D Common Stock 2026-08-07 4 S 0 8000 104.38 D 19360 I By Sessions LLC Common Stock 2026-08-07 4 S 0 10000 104.68 D 9360 I By Sessions LLC Stock Option (Right to Buy) 10.39 2026-08-07 4 M 0 5000 0 D 2033-11-22 Common Stock 5000 45000 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. /s/ Heidy King-Jones, as Attorney-in-Fact 2026-08-10